

DOCKET NO.: CELG-0422

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Jerome B. Zeldis, et al.

Confirmation No.: 8455

Application No.: 10/820,397

Group Art Unit: 1614

Filing Date: April 8, 2004

Examiner: Not Yet Assigned

For: METHODS FOR TREATMENT OF COGNITIVE AND MENOPAUSAL
DISORDERS WITH D-THREO METHYLPHENIDATE

DATE OF DEPOSIT: September 12, 2005

I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID,
ON THE DATE INDICATED ABOVE AND IS
ADDRESSED TO THE UNITED STATES PATENT AND
TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA,
VA 22313-1450.

TYPED NAME: Heather Kite

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☒ Copies of reference numbers 150-205 listed on the attached Form PTO-1449 are enclosed herewith.

- ☒ Copies of reference numbers 148-149 listed on the attached Form PTO 1449 are not required to be submitted pursuant to the revisions of 37 CFR § 1.98(a)(2)(i).

☐ Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date:

Sept 12, 2005



Walter C. Frank

Registration No. 52,911

WOODCOCK WASHBURN LLP

One Liberty Place - 46th Floor

Philadelphia, PA 19103

Telephone: (215) 568-3100

Facsimile: (215) 568-3439

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CELG-0422	Application No. 10/820,397
		Applicant Jerome B. Zeldis, et al.	
		Filing Date April 8, 2004	Group 1614
		Confirmation No. 8455	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
/D.S./	150	Aoyama, T. et al., "Pharmacodynamic Modeling for Change of Locomotor Activity by Methylphenidate in Rats," <i>Pharmaceutical Research</i> , 1997, 14(11), 1601-1606	
	151	Aoyama, T. et al., "Pharmacokinetics and pharmacodynamics of methylphenidate enantiomers in rats," <i>Psychopharmacology</i> , 1996, 127, 117-122	
	152	Aoyama, T., et al., "Nonlinear kinetics of threo-methylphenidate enantiomers in a patient with narcolepsy and in healthy volunteers," <i>Eur. J. Clin. Pharmacol.</i> , 1993, 44, 79-84	
	153	Barkley, R. A., et al., "The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study," <i>J. Am. Acad. Adolesc. Psychiatry.</i> , 1990, 29(4), 546-557	
	154	Baughman, Jr., F. A., "Treatment of Attention-Deficit/Hyperactivity Disorder," <i>JAMA</i> , April 28, 1999, 281(16), 1490-1491	
	155	Bruera, E., and Neumann, C. M., "The uses of psychotropics in symptom management in advanced cancer," <i>Psycho-Oncology.</i> , 1998, 7, 346-358	
	156	Carey, W. B., "What the multimodal treatment study of children with attention-deficit/hyperactivity disorder did and did not say about the use of methylphenidate for attention deficits," <i>Pediatrics</i> , 2000, 863-864	
	157	Chapin, R. et al., "Methylphenidate hydrochloride," <i>Environmental Health Perspectives</i> , 1997, 105 (supp 1), 319	
	158	Coyle, J. T., "Psychotic drug use in very young children," <i>J. Am. Med. Assn.</i> , 2000, 283(8), 1059-1060	
/D.S./	159	Davids, E. et al., "Stereoselective effects of methylphenidate on motor hyperactivity in juvenile rats induced by neonatal 6-hydroxydopamine lesioning," <i>Psychopharmacology</i> , 2002, 160, 92-98	

EXAMINER

/Darryl Sutton/

DATE CONSIDERED

03/14/2008

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CELG-0422	Application No. 10/820,397
		Applicant Jerome B. Zeldis, et al.	
		Filing Date April 8, 2004	Group 1614
		Confirmation No. 8455	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
/D.S./	160	Ding, Y.-S. et al., "Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and l-threo-methylphenidate in the human and baboon brain," <i>Psychopharmacology</i> , 1997 , 131, 71-78	
	161	Ding, Y.-S. et al., "Is the L-threo Enantiomer of Methylphenidate (Ritalin) Inactive in the Brain when the Drug is Given Orally?" <i>ACNP 41st Annual Meeting</i> , December 8-12, 2002 , Scientific Abstract No. 119	
	162	Garland, E. J., "Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats," <i>J. Psychopharmacology</i> , 1998 , 12(4), 385-395	
	163	Golden, G. S., "Role of attention deficit hyperactivity disorder in learning disabilities," <i>Seminars in Neurology</i> , 1991 , 11(1), 35-41	
	164	Goldman, L. S., et al., "Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents," <i>J. Am. Med. Assn.</i> , 1998 , 279(14), 1100-1107	
	165	Jadad, A. R., et al., "Review: Pharmacologic interventions are more effective than non-pharmacologic for attention-deficit hyperactivity disorder," <i>Therapeutics, ACP Journal Club</i> , November/December 2000 , 110	
	166	Jensen, P. S., et al., "Are stimulants over-prescribed? Treatment of ADHD in four U.S. communities," <i>J. Am. Acad. Adolesc. Psychiatry</i> , 1999 , 37(7), 797-804	
	167	Jonkman, L.M. et al., "Differences in plasma concentrations of the D- and L-threo methylphenidate enantiomers in responding and non-responding children with attention-deficit hyperactivity disorder," <i>Psychiatry Research</i> , 1998 , 78, 115-118	
	168	Kimko, H.C. et al., "Pharmacokinetics and Clinical Effectiveness of Methylphenidate," <i>Clin Pharmacokinetics</i> , Dec. 1999 , 37(6), 457-470	
/D.S./	169	LeFever, G. B., et al., "The extent of drug therapy for attention deficit-hyperactivity disorder among children in public schools," <i>American Journal of Public Health</i> , (Sept., 1999) , (89)9, 1359-1364	

EXAMINER

/Darryl Sutton/

DATE CONSIDERED

03/14/2008

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CELG-0422		Application No. 10/820,397	
	Applicant Jerome B. Zeldis, et al.			
	Filing Date April 8, 2004		Group 1614	
	Confirmation No. 8455			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/D.S./	170	Lin, J. H., and Lu, A. H., "Role of pharmacokinetics and Metabolism in drug discovery and development," <i>Pharmacological Reviews</i> , 1997, 49(4), 403-449
	171	Llana, M. E. and Crismon, M. L., "Methylphenidate: increased abuse or appropriate use?" <i>J. Amer. Pharmaceut. Assn.</i> , 1999, 39(4), 526-530
	172	MacDougall, M. K., et al., "Symptom control in the pregnant cancer patient," <i>Seminars in Oncology</i> , 2000, 27(6), 704-711
	173	Markowitz, J. S., et al., "Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methyl phenidate formulations," <i>Pharmacotherapy</i> , October 2003, 23(10), 1281-1299
	174	McCarthy, M., "USA to improve care of children with ADHD," <i>The Lancet</i> , 2000, 355, 1161
	175	Mehta, M. A., et al., "Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain," <i>J. Neurosci.</i> , 2000, 20RC65: (1-6)
	176	Modi, N. B. et al., "Dose-Proportional and Stereospecific Pharmacokinetics of Methylphenidate Delivered Using an Osmotic, Controlled-Release Oral Delivery System," <i>J Clin Pharmacol</i> , 2000, 40, 1141-1149
	177	Patrick, K.S. et al., "Pharmacology of Methylphenidate, Amphetamine Enantiomers and Pemoline in Attention-Deficit Hyperactivity Disorder," <i>Human Psychopharmacology</i> , 1997, 12, 527-546
	178	Quinn, D.M.P., "Methylphenidate: The Role of the d-Isomer," undated, Department of Psychiatry, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada, 369-373
	179	Rouhi, A.M., "Chirality at Work," <i>C&EN</i> , May 5, 2003, 56-61
/D.S./	180	Schweitzer J. B., et al., "Attention deficit hyperactivity disorder," <i>Adv. Pathophysiol. And Treat. Psychiatric Disorders: Implications for Internal Med.</i> , 2001, 85(3), 757-777

EXAMINER

/Darryl Sutton/

DATE CONSIDERED

03/14/2008

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CELG-0422	Application No. 10/820,397
		Applicant Jerome B. Zeldis, et al.	
		Filing Date April 8, 2004	Group 1614
		Confirmation No. 8455	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
/D.S./	181	Shader R.I. et al., "Population Pharmacokinetics of Methylphenidate in Children with Attention-Deficit Hyperactivity Disorder," <i>J Clin Pharmacol</i> , 1999 , 39, 775-785	
	182	Spencer, T., et al., "Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle," <i>J. Am. Acad. Adolesc. Psychiatry</i> , 1996 , 35(4), 409-432	
	183	Srinivas, N.R. "Role of Stereoselective Assays in Bioequivalence Studies of Racemic Drugs: Have We Reached a Consensus?" <i>J Clin Pharmacol</i> , February 2004 , 44, 115-119	
	184	Srinivas, N.R., et al., "Enantiomeric Drug Development: Issues, Considerations, and Regulatory Requirements," <i>Journal of Pharmaceutical Sciences</i> , September 2001 , 90(9), 1205-1215	
	185	Stein, M. A., et al., "Methylphenidate dosing: Twice daily versus three times daily," <i>Pediatrics</i> , 1996 , 98(4), 748-756	
	186	Swanson, J. M., et al., "Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children," <i>Clin. Pharmacology and Therapeut.</i> , 1999 , 66(3), 295-305	
	187	Swanson, J. M., et al., "Analog classroom assessment of Adderall in children with ADHD," <i>J. Am. Acad. Adolesc. Psychiatry</i> , 1998 , 37(5), 519-525	
	188	Taylor, M. A., "Attention-deficit hyperactivity disorder on the frontlines: Management in the primary care office," <i>Comp. Ther.</i> , 1999 , 25(6/7), 313-325	
	189	Teo, S. K., et al., "A 90-day oral gavage toxicity study of D-methylphenidate and D,L-methylphenidate in beagle dogs," <i>Internat. J. Toxicol.</i> , 2003 , 22, 215-226	
	190	Teo, S. K., et al., "A single-dose, two-way crossover, bioequivalence study of dexamethylphenidate HCl with and without food in healthy subjects," <i>J. Clin. Pharmacol.</i> , February 2004 , 44, 173-178	
/D.S./	191	Teo, S. K., et al., "D-Methylphenidate and D,L-methylphenidate are not developmental toxicants in rats and rabbits," <i>Birth Defects Research (Part B)</i> , 2003 , 68, 162-171	
EXAMINER		/Darryl Sutton/	DATE CONSIDERED 03/14/2008

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CELG-0422	Application No. 10/820,397
		Applicant Jerome B. Zeldis, et al.	
		Filing Date April 8, 2004	Group 1614
		Confirmation No. 8455	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
/D.S./	192	Teo, S. K., et al., "D-Methylphenidate is non-genotoxic in <i>in vitro</i> and <i>in vivo</i> assays," <i>Mutation Research</i> , 2003 , 537, 67-69	
	193	Teo, S. K., et al., "Neurobehavioral effects of racemic <i>threo</i> -methylphenidate and its D and L enantiomers in rats," <i>Pharmacology, Biochemistry, and Behavior</i> , 2003 , 74, 747-754	
	194	Teo, S., et al., "A 90-day oral gavage toxicity study of D-methylphenidate and D,L-methylphenidate in Sprague-Dawley rats," <i>Toxicology</i> , 2002 , 179, 183-196	
	195	Teo, S.K. et al., "The perinatal and postnatal toxicity of D-methylphenidate and D,L-methylphenidate in rats," <i>Reproductive Toxicology</i> , 2002 , 16, 353-366	
	196	Thai, D.L., et al., "Comparative Pharmacokinetics and Tissue Distribution of the <i>d</i> -enantiomers of Para-substituted Methylphenidate Analogs," <i>Drug Metabolism and Disposition</i> , 1999 , 27(6),	
	197	Thomson, M.R. et al., "Enantioselective Transesterification of Methylphenidate to Ethylphenidate After Coadministration with Ethanol," <i>Thirty-First Annual ACCP Meeting Abstracts</i> , Abstract No. 80, 2002	
	198	Tripp, G. and Alsop, B., "Sensitivity to reward frequency in boys with attention deficit hyperactivity disorder," <i>J. Clin. Child Psychology</i> , 1999 , 28(3), 366-375	
	199	Volkow, N. D. et al., "Mechanism of action of methylphenidate: Insights from PET imaging studies," <i>Journal of Attention Disorders</i> , 2002 , 9(Suppl. 1/2002), S-31 - S43	
	200	Volkow, N.D. et al., "Effects of Methylphenidate on Regional Brain Glucose Metabolism in Humans: Relationship to Dopamine D ₂ Receptors," <i>Am J Psychiatry</i> , January 1997 , 154(1), 50-55	
/D.S./	201	Volkow, N.D. et al., "Temporal relationships between the pharmacokinetics of methylphenidate in the human brain and its behavioral and cardiovascular effects," <i>Psychopharmacology</i> , 1996 , 123, 26-33	

EXAMINER

/Darryl Sutton/

DATE CONSIDERED

03/14/2008

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CELG-0422	Application No. 10/820,397
		Applicant Jerome B. Zeldis, et al.	
		Filing Date April 8, 2004	Group 1614
		Confirmation No. 8455	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
/D.S./	202	Ward, M. F., et al., "The Wender Utah rating scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder," <i>Am. J. Psychiatry.</i> , 1993 , 150(6), 885-890	
	203	Weiler, M. D., et al., "Mother and Teacher Reports of ADHD Symptoms: DSM-IV Questionnaire Data," <i>J. Am. Acad. Child Adolesc. Psychiatry</i> , September 1999 , 38(9), 1139-1147	
	204	Zametkin, A. J. and Ernst, M., "Problems in the management of attention-deficit/hyperactivity disorder," <i>New. Eng. Jour. Med.</i> , 1999 , 340(1), 40-46	
/D.S./	205	Zito, J. M., et al., "Trends in the prescribing of psychotropic medications to preschoolers," <i>J. Am. Med. Assn.</i> , 2000 , 283(8), 1025-1030	

© 2005 WW

EXAMINER

/Darryl Sutton/

DATE CONSIDERED

03/14/2008